安罗替尼治疗多线化疗后进展晚期卵巢癌的疗效观察(3)
[2] Audeh MW， Carmichael J， Penson RT， et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer： a proof-of-concept trial. Lancet， 2010， 376(9737)：245-251.[3] Kristeleit R， Shapiro GI， Burris HA， et al. A phase Ⅰ-Ⅱ study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res ......
您现在查看是摘要页，全文长 3105 字符。